iLymph is an interdisciplinary clinical and translational research program aiming at combining biomarker-driven and risk-adapted management approaches in patients with malignant lymphoproliferative diseases.

The The iLymph research program aims at developing and validating biomarkers for: (1) early detection, disease progression, and recurrence of lymphoid malignancies; and, (2) risk assessment of patients with lymphoid malignancies (of B- or T-cell origin) in both the immunocompetent and immunodeficient clinical setting. As a support to these activities, iLymph projects also include development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with lymphoid diseases. The principles contained in the iLymph initiative are in accordance with the NCI's Strategic Plan to support studies to better understand risk reduction, prevention, early detection, diagnosis, and treatment. The iLymph projects include proteomic, genomic, epigenomic, and transcriptomic analyses, as well as the utilization of standardized biospecimens for validation studies.

The organization of the iLymph project relies on three main clusters of activities: (i)interdisciplinary projects, (ii) methodological toolboxes and (iii) coordinating and administrative functions.

The structure of the iLymph strategic research project relies on three basic domains: (i) search for predictive biomarkers, (ii) search for prognostic factors, (iii) performance of personalized, risk-adapted clinical intervention. The translational results will be evaluated for clinical implementation in phase I, II or III trials, some of which are ongoing. The clinical trial activity will be coordinated and supported by the academic clinical trial office (A-CTO) linked to iLymph and located at the Dept. of Hematology, AUH.

More about iLymph.

about A-CTO.

Revised: 7 December 2017